Heparin Market Size By Product (Low Molecular Weight Heparin, Unfractionated Heparin), By Source (Porcine, Bovine), By Application (Venous Thromboembolism, Atrial Fibrillation/Flutter, Coronary Artery Disease), Distribution Channel & Forecast, 2022 - 2028

Industry Overview

Heparin Market size accounted for over USD 4.5 billion in 2021 and is estimated to grow at 2.8% CAGR between 2022 and 2028. Rising geriatric population base across regions is one of the major factors contributing to the overall market growth. Geriatric population is noted to be relatively more prone to orthopaedic disorders such as arthritis and osteoporosis, among others. As a significant proportion of patients require surgical interventions for optimum treatment, the demand for heparin is anticipated to rise, thereby augmenting the market statistics.
 

To get more details on this report: Request Free Sample PDF
 

For instance, in 2021, it was estimated that there were more than 350 million people who have arthritis globally. Thus, rising number of elderly populations suffering from orthopaedic disorders surges the demand for surgical treatment, thereby accelerating the industry expansion.
 

Heparin is a naturally occurring glycosaminoglycan that occurs naturally. Heparin is used as an anticoagulant in medicine primarily to prevent the formation of blood clots. It is particularly used for the treatment of unstable angina and heart attacks. Heparin is also used in the treatment of variety of health problems, such as deep vein thrombosis, acute coronary syndrome, atrial fibrillation, and pulmonary embolism, as well as hemofiltration during cardiac surgery and cardiopulmonary bypass.
 

The COVID-19 pandemic was noted to have a slight optimistic impact on heparin industry, augmenting the top-line revenue for several key manufacturers. Moreover, owing to the increasing number of patients suffering from COVID-19, the demand for heparin was also noted to rise as it helps subdue the effects of respiratory diseases and also assists in thinning the blood.
 

Additionally, all individuals admitted to the hospital with COVID-19 are treated with prophylactic-dose of low-molecular-weight heparin, thereby fostering the demand in the market. Furthermore, prominent companies in the market were noted to register stronger financial performance, thereby supplementing the industry growth.
 

Growing prevalence of chronic diseases is expected to boost the market outlook

Increasing prevalence of chronic diseases such as cancer, heart disease, stroke, diabetes, and arthritis across the globe will boost the global market statistics. For instance, in 2021, according to the Centers for Disease Control (CDC), approximately 659,000 people in the U.S. die from a heart-related disorder annually, that is 1 in every 4 deaths in the country.
 

Thus, rising number of patients suffering from cardiovascular disorders has led to an increase in the demand for heparin, thereby propelling the industry landscape. Moreover, rising prevalence of chronic diseases in middle aged and geriatric people will further accelerate the market forecasts.
 

Side effects associated with the usage of heparin may hamper market growth

Side effects associated with the usage of heparin are the major factors restraining the market growth. One of the prominent side effects associated with heparin is bleeding. Heparin causes spontaneous bleeding from various places in the body that include surgical sites or open wounds, ovaries & uterus, intestines, stomach, gums, and mouth.
 

This is caused due to heparin-induced thrombocytopenia (HIT), a condition in which heparin induces the immune system of body to produce antibodies against its own platelets leading to the risk of bleeding owing to the reduction in platelets. This largely affects the product’s adoption rate and is expected to hamper the industry outlook.
 

Low molecular weight heparin segment is expected to dominate throughout the analysis period

To get more details on this report: Request Free Sample PDF
 

By product, the heparin market is segmented into low molecular weight heparin and unfractionated heparin. The low molecular weight heparin segment is anticipated to witness over 3% CAGR between 2022 and 2028. Low molecular weight heparin (LMWH) is used for the treatment and prevention of pulmonary embolism (PE), deep vein thrombosis (DVT) and myocardial infarction (heart attack).
 

For instance, according to the Centers for Disease Control and Prevention (CDC), approximately 900,000 people in the U.S. are affected by DVT/PE annually. As LMWHs are used in the treatment of such disorders, their rising incidence rate will boost the market size.
 

Presence of porcine-based products in key markets will drive the industry scenario

By source, the heparin market is fragmented into porcine and bovine. Porcine segment is anticipated to register more than 2.7% CAGR over the forecast period. In mature markets such as countries of North America and Europe, mostly porcine-based heparin products are permitted for commercialization, thereby the segment is noted to predominantly drive the market statistics. Moreover, the porcine-based heparin is widely used to treat patients suffering from atrial fibrillation as it prevents blood clots, thereby fostering the market statistics.
 

Rising awareness of thrombosis is expected to boost the market share

By application, the heparin market is classified into venous thromboembolism, atrial fibrillation/flutter, coronary artery disease and others. Venous thromboembolism segment accounted for around 52% revenue proportion in 2021 and is forecast to witness significant growth throughout the analysis timeframe Rising awareness of thrombosis among the population is expected to primarily boost the market growth. For instance, the introduction of online and virtual learning by International Society on Thrombosis and Haemostasis, Inc. is expected to increase the awareness of thrombosis among the population, thereby supplementing the segmental demand.
 

Rising number of surgeries is expected to spur the market growth over the coming years

By distribution channel, the heparin market is fragmented into hospital pharmacy, retail pharmacy and online pharmacy. Hospital pharmacy segment is anticipated to surpass USD 2.9 billion by 2028. Increasing number of hospital admissions for the treatment and surgeries is expected to boost the segmental growth. In addition, patients prefer hospitals owing to benefits such as ease of availability of medicines and relatively better quality of care, thereby supplementing the business landscape.
 

Presence of significant market players will foster the regional business expansion

To get more details on this report: Request Free Sample PDF
 

North America heparin market was valued at over 777.5 million in 2021 due to the presence of significant market players such as Pfizer and Amphastar, among others. Moreover, increasing prevalence of chronic diseases in the countries of North America is expected to boost the regional market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), approximately 5% to 8% of the U.S. population has one of several genetic risk factors, also known as inherited thrombophilia, in which a genetic defect can be identified increasing the risk for thrombosis. Thus, increasing risk of thrombosis will increase the demand of heparin. U.S. heparin industry is poised to grow at over 7.2% CAGR between 2020 and 2026 owing to rising demand for anticoagulant products will drive the regional market size.
 

Product approvals will create numerous growth opportunities for industry players

Few of the notable industry players operating in global heparin market are Amphastar, Leo Pharma, Pfizer, Rovi, Sanofi and Shenzhen Hepalink among others. These industry players implemented various strategies such as mergers and acquisitions, collaborations, new product launch, etc. in order to capture high revenue share in the market.
 

Some of the recent industry developments:

• In May 2019, Pfizer, Inc. received approval from US Food and Drug Administration (FDA) for its anticoagulant medicine Fragmin (dalteparin sodium). It is used to minimize the recurrence of venous thromboembolism (VTE) in pediatric patients aged one month and above. This strategy enabled the company to strengthen its product portfolio and market position.
   
• In June 2018, Amphastar Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for Semi-Purified Heparin at the company’s subsidiary, Amphastar Nanjing Pharmaceuticals (“ANP”) and the manufacture of heparin sodium USP at International Medication Systems, Limited. This strategy enabled company to add value to its business portfolio by strengthening its product offerings.
   

The heparin market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028, for the following segments:

Click here to Buy Section of this Report

By Product

• Low molecular weight heparin
• Unfractionated heparin

By Source

• Porcine
• Bovine

By Application

• Venous thromboembolism
• Atrial fibrillation/flutter
• Coronary artery disease
• Others

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Poland
  • Austria
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE